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Review of the Utility of Cholinesterase Testing Methods

Introduction
Acetylcholine (ACh) is the most widespread and studied neurotransmitter involved with nerve transmission. Research in the early 1900s suggested that an esterase was involved with the inactivation of ACh and its removal from circulation. The first extract of cholinesterase (ChE) was prepared from horse serum and reported in 1932 by Stedman et al. Since that landmark publication, ChEs from different species have been identified and found to differ in substrate specificity and susceptibility to inhibitors (Giles, 2007) . A number of schemes for naming the various ChEs was proposed, but the currently accepted one (Silver, 1974 ) is based on a family of enzymes with substrate preferences that fall into two broad categories: (1) Acetylcholinesterases (AChEs), which preferentially hydrolyze acetyl esters such as ACh, and; (2) butyrylcholinesterases (BChEs), which preferentially hydrolyze other esters such as butyrylcholine. Table 1 -1 provides a summary and comparison of AChEs and BChEs. The primary biological role of AChE is the rapid hydrolysis of ACh at the cholinergic synapses in the Central and Peripheral Nervous Systems (CNS/PNS) and at neuromuscular junctions. The inhibition of AChE by certain xenobiotic chemicals (e.g., organophosphate pesticides) within synaptic clefts results in the dysfunction of nerve transmission by preventing the inactivation of ChE; this leads to excessive stimulation of the CNS/PNS.
The AChE protein has three isoforms produced by alternative splicing of pre-mRNA, and each isoform also has non-catalytic roles such as cell growth and adhesion (Grisaru et al., 1999) . The specific biological roles of these isoforms are not necessarily the same, and the distribution of AChE isoforms varies among different tissues and during different stages of development. Nonetheless, experiments have demonstrated that the different molecular forms of AChE have identical catalytic properties (Schwarz et al., 1995) . The synaptic isoform (AChE-S) is produced and found primarily in brain and muscle tissues, while the "erythrocytic" isoform (AChE-E) is anchored to red blood cell (RBC) membranes and, hence, is also called RBC cholinesterase. Since obtaining the AChE-S from cholinergic synapses is very invasive and impractical for routine testing purposes, the AChE-E associated with RBCs is usually sampled as a surrogate indicator of AChE inhibition in the CNS/PNS.
Unlike AChE, the greatest concentration of BChE is found in the liver, although it is readily found in and sampled from the blood plasma (i.e., plasma cholinesterase). The biological role of BChE is not fully understood. Although BChE hydrolyzes ChE, the suggested role of BChE is a scavenging enzyme for the detoxification of naturallyoccurring compounds (Grisaru et al., 1999) . The ambiguous role of BChE is illustrated in rare individuals born with a mutated or missing BChE gene. These individuals live without any apparent physiological consequences. However, if they undergo surgery, post-operative apnea may result when tracheal intubation is used with the muscle relaxants succinylcholine or mivacurium (Darvesh et al., 2003) . Research also suggests that BChE is in some way involved in a number of neurodegenerative diseases (Darvesh et al., 2003) , and BChE levels are inversely related to risks for cardiovascular disease (Calderon-Margalit et al., 2006) .
Relevance of Cholinesterase Testing for Medical and Public Health Purposes
The primary reason for measuring ChE is related to human exposure from certain pesticides that act as ChE-inhibitors, most notably the organophosphates (OPs, and other phosphorous-based compounds) and the carbamates. More than 200 OPs and 25 carbamates have been formulated into thousands of different products (Kwong, 2002) . The widespread and global use of pesticides, along with poor health surveillance statistics, makes it difficult to estimate the actual number of exposures, illnesses, and deaths resulting from pesticides. Nevertheless, some estimates of the global health problem include more than 3 million poisonings and 200,000 deaths per year, with the majority of these incidents reported as intentional (Jeyaratnam, 1990) . Based on a literature survey by Jaga and Dharmani (2003) , the most likely situations involving exposures to OPs in the U.S. are outlined in Table 1 -2. Accidental poisoning and suicidal poisoning are possible in both occupational and nonoccupational exposures.
The health consequences of ChE inhibition can range from immediately life-threatening to subtle. Although a great number of symptoms can occur from acute, high exposures to OPs, death is believed due to the inhibition of respiratory centers in the brainstem, resulting respiratory in failure (Lotti, 2001) . Another clinical manifestation of OP toxicity is called the "intermediate syndrome," which is characterized weakness of respiratory, neck and proximal limb muscles (Costa, 2006) . This intermediate syndrome is not a direct effect of ChE inhibition and occurs several hours after the signs and symptoms of severe ChE-inhibition have occurred (Senanayake and Keralliedde, 1987) . Some OPs can produce a form of toxicity known as organophosphate-induced delayed polyneuropathy (OPIDP); in this case, the neuropathy occurs one to three weeks following exposure and involves weakness of the extremities, and neurodegeneration progressing to ataxia and paralysis. OPIDP appears to result from OP inhibition of neuropathy target esterase, an enzyme involved with lipid metabolism in the axonal membranes. (Glynn, 2006) . There are also many unresolved issues regarding OP toxicity, some of which are listed in Table  1 -3. What are the precise molecular events involved in axonal degeneration?
Are additional targets relevant for some aspects of OP toxicity?
The measurement of ChE to estimate the exposure or effects from ChE-inhibitors has been proposed and studied since the landmark publication of Stedman et al. in 1932. However, the first formal guidance in the U.S. for using ChE testing was in 1971 by the American Medical Association's Committee on Occupational Toxicology, Council on Occupational Health (Milby, 1971) . Another authoritative document was published in 1976 by the National Institute for Occupational Safety and Health (NIOSH) as a criteria document for occupational exposure to parathion (NIOSH, 1976) . This document provided an extensive literature review that related ambient exposures to OPs with the depression of ChE activity and suggested that 70% inhibition of AChE activity in the RBCs is "significant." Over the years, many other documents have become available that provide guidance on the use of ChE testing for medical and public health purposes (Weese, 2005; California Environmental Protection Agency (Cal/EPA, 2002; Lessenger and Reese, 1999) .
The overall importance of ChE testing is dependent on the types of decisions made by clinicians and public health professionals. For clinical decision-making that involves acute poisoning, the value of ChE test data for the diagnosis, treatment, and management of patients often depends on whether or not the poison is known or suspected to be a ChE-inhibitor, and whether the patient has baseline or pre-exposure ChE test data available (Lessenger and Reese, 1999) . On the other hand, ChE test data is quite valuable for medical surveillance and/or biological monitoring of known or suspected exposures to OPs or carbamates.
In the latter situation, the decision usually involves whether to remove employees from workplace exposures to OPs or carbamates (Cal/EPA, 2002) . In general, ChE testing is considered more valuable for decision-making that involves medical surveillance or biological monitoring than for clinical diagnosis and treatment of acute poisoning.
Using ChE testing data for health decisions is inherently complicated for several reasons. Certain pesticides have preferential affinities for either AChE or BChE (Cal/EPA, 2002) . In addition, great differences exist in the reactivation rates of either AChE or BChE after exposure to various inhibitors. For example, the OPs generally bind more strongly to AChE, and enzyme reactivation is slow compared with the carbamates. Even among the OPs, the binding capacity to AChE can differ because of different molecular structures of the OPs (Kwong, 2002) . Some OPs bind irreversibly to AChE and chemically alter the enzyme over different periods of time, a process called "aging," which completely inactivates the enzyme (Costa, 2006) . Another reason is the variable timing of AChE and BChE inhibition/reactivation due to the toxicokinetics of different pesticides (Kwong, 2002) . Some of the factors influencing the toxicokinetics are the pesticide's chemical structure and individual variation in pesticide metabolism (Furlong et al., 2000) .
Other reasons that make using ChE testing data complicated include the inter-and intraindividual variability of ChE activity and its relationship to clinical signs and symptoms. The variability of AChE activity between individuals based simply on genetics, sex, race, or age is estimated as high as 23% (Lessenger and Reese, 1999) . This underscores the importance of having individual baseline values of ChE activity when assessing exposures to ChE-inhibitors, although some methods of developing postexposure baselines have been proposed (Lessenger and Reese, 1999) . The extent of intraindividual variability is controversial and can be influenced by a number of factors such as disease, medications taken, and unknown exposures to ChE-inhibiting substances (Lefkowitz et al., 2007; Costa, 2006; Mason and Lewis, 1989) . The variability of ChE activity among individuals confounds clinical diagnosis, because the signs and symptoms of CNS/PNS poisoning do not necessarily correlate with the level of ChE activity in the blood (Weese, 2005; Lessenger and Reese, 1999) .
Finally, an important source of variability that complicates decision-making for ChE testing is the sampling, handling and storage, preparation, and analysis of blood specimens. This analytical variation is particularly important when meaningful comparisons of serial ChE tests are needed (Cal/EPA, 2002) . In addition, with various methods of performing ChE testing available, the results between laboratories using different methods are not directly comparable. This subject and the most commonly used methods of ChE testing are discussed in the next section.
Laboratory Testing Methods
At least six methods for ChE testing have been used in laboratories (Vandekar, 1980) . Various novel and improvised methods for ChE testing are reported and proposed in the scientific literature. Nonetheless, the most commonly used assays for routine ChE testing are limited to three categories (Wilson, 2005 ):
1. The delta pH method by Michel (1949) .
2. The radioactive ACh method of Johnson and Russell (1975) .
3. The kinetic assays pioneered by Ellman et al. (1961) .
The delta pH method of ChE testing is considered a kinetic assay that measures the change of pH in a specified period of time (e.g., one hour) and is usually reported in units of delta pH per hour (hr). The basic principle of the test is based on the addition of the substrate ACh bromide to either separated RBCs or plasma; the ACh is hydrolyzed by the ChE to produce acetic acid and choline, which results in pH changes. The U.S. Army's Cholinesterase Reference Laboratory uses a modification of the delta pH method for AChE so that testing can be done within 17 minutes of reaction time, and the results are then converted to delta pH/hr (USACHPPM, 2005).
The U.S. Army Center for Health Promotion and Preventive Medicine (USACHPPM) probably ranks first in the world for the number of tests performed using the delta pH method. Each year over 15,000 personnel are biologically monitored by the USACHPPM's Cholinesterase Reference Laboratory (Wilson, 2006) . The USACHPPM also has a highly refined and consistent quality assurance program. In a recent report by Lefkowitz et al. (2007) , the variability of AChE activity in individuals was analyzed by USACHPPM and determined to be negligible over several decades. This suggests that much of the controversy surrounding intraindividual variability may be due to differences in analytical methods and techniques among laboratories. Despite its successful use by the USACHPPM, the delta pH method is slow and has low throughput, which limits its feasibility by commercial laboratories.
The radioactive ACh method is a micro-assay that measures hydronium products produced from 3H-labeled ACh following enzymatic reaction and organic/water extraction. Although this method is accurate and suitable for multiple determinations of ChE activity, it is expensive and has radioactive waste disposal problems (Wilson, 2005) . Consequently, this method is not commonly offered by commercial laboratories. Several different kinetic assays use thiocholine substrates to measure ChE activity, but the most common assay is the Ellman method (Wilson, 2005) . This method measures hydrolysis of the substrate acetylthiocholine (ATCh) by either BChE or AChE (depending upon blood sample preparation) to yield acetate and thiocholine. The latter product reacts with 5, 5'-dithiobis-2-nitrobenzoic acid to produce a yellow-colored acid anion (5-thio-thionitrobenzoic acid) that can be measured with a spectrophotometer. The results are typically expressed as micromoles per minute per milliliter (µmol/min/mL) or international activity per milliliter (U/mL). Several commercial laboratory kits are produced based on the Ellman method, and many variations of the method have been published.
A problem with using different methods for ChE testing comes from comparing the results of periodic or serial testing. As mentioned previously, the baseline or trend of ChE activity for an individual is important for making meaningful assessments of exposure to and recovery from ChE-inhibitors. However, direct comparisons between the between the various methods are not possible. In an effort to generate conversion factors for comparing the results between delta pH and Ellman methods, the U.S. Army Medical Research and Materiel Command (USAMRMC) contracted with the University of California at Davis (UC Davis) to study the variability and reliability of these methods by using split samples, and by "spiking" samples with ChE-inhibitors (Wilson, 2006) . The early results of the UC Davis study showed that the Ellman method is more sensitive at higher AChE activity levels than the delta pH method (Wilson, 2006) . This suggests that the Ellman method is better at detecting early warning signs of exposure to AChEinhibitors, i.e., low levels that slightly suppress AChE activity. Conversion factors were also developed to permit comparison of the two methods, and a study is ongoing using a variety of OPs to inhibit ChE in volunteer blood samples.
Several new laboratory methods for analysis of ChE levels have been developed and reported in recent years. Gordon et al. (2004) 
Field-Testing Kits
The most widely used field-testing system for ChE is called the Test-mate™, which is manufactured by EQM Research, Inc. (Cincinnati, OH) . Although a new model of Testmate™ is planned for production, the latest commercially-available system is the Model 400 Test-mate™ ChE (Wilson, 2006) . This unit requires only 10 microliters (µL) of blood, and the entire assay can be completed in less than 4 minutes (min). The Testmate™ is the only known field-testing kit for ChE that is "approved" by the U.S. Food and Drug Administration (FDA) (see Section 2.2).
The Test-mate™ ChE system is a variation of the Ellman method. It can specifically measure either AChE or BChE, depending on which assay kit with ChE-inhibiting reagents is used with the system. The system also measures hemoglobin and an internal reagent blank to refine photometric measurements; the ChE activity is measured with a compact photometric analyzer. The results are normalized to 25°C, and also to the hemoglobin concentration for AChE (Taylor et al., 2003) . The results are usually expressed in U/mL, or alternatively for AChE as activity per gram of hemoglobin (U/g Hgb).
Through the contract mentioned previously with the USAMRMC, the performance of the Test-mate™ system was compared with the laboratory-based Ellman and Delta pH methods (Wilson, 2006) . In general, the Test-mate™ has a good agreement with the Ellman and Delta pH methods over most of AChE activity range. However, the Ellman method appears to be more sensitive at highest levels of AChE activity, i.e., less exposure and consequently less AChE depression. Regression formulas were also derived to permit the conversion of results among the three different methods.
Another commercially available field-testing method is the Lovibond Cholinesterase AF 267 Test Kit. This product is marketed as a rapid test of exposure to OP insecticides to alert users of overexposure and unsafe work practices. The company advertises that the kit is specified in the World Health Organization's technical information sheet No. 356 (WHO, 1967) . Unlike the Test-mate™, this field testing method utilizes a color comparator rather than photometric analyzer (Da Silva et al., 1994) . This suggests that the method is a relatively crude estimation of ChE activity compared with the Testmate™.
Military Applications and Policies Regarding Cholinesterase Testing
All of the military services are required to comply with Department of Defense (DoD) policies regarding occupational safety and health programs (DoD, 2007 Diagnostics, 2007) .
Another very important application of ChE testing by the military involves uniformed and civilian personnel who handle chemical warfare agents (CWAs) and munitions such as sarin, soman, and tabun. These situations have special requirements known as "surety" that emphasize safety, security, and personal reliability (U.S. AR 50-6). The chemical demilitarization program is particularly important because of its size and scope. The Cholinesterase Reference Laboratory (CRL) at USACHPPM has primary responsibilities for ChE testing of surety workers (DA PAM 40-8, TB MED 590). As mentioned previously, the CRL uses the Delta pH method, and for routine analyses, specifically measures AChE activity of the RBCs. The CRL maintains a massive database of AChE test results for over 15,000 personnel, and most of them have multiple test results in the database. The estimated annual number of AChE tests performed at the CRL is 25,000.
The historical test results for many individuals span decades over time (Lefkowitz et al., 2007) .
Chemical warfare defense on the battlefield is a military-specific application of ChE testing, although recent concerns about terrorist attacks have gained the interest of civilian agencies in using ChE testing for homeland security. Since many of the CWAs are nerve agents that specifically inhibit ChEs, the depression of ChE is considered a quick and easy biomarker of exposure to these agents (TB MED 296 (Science Applications International Corporation, 1998) .
Despite the lack of a uniform policy for ChE testing across the services for CWAs, a policy regarding ChE testing frequency and acceptable methods does exists for occupational medical surveillance of pesticide workers. According to the DoD Occupational Medical Examinations and Surveillance Manual (2007), a worker with potential exposures to cholinesterase-inhibiting pesticides must have both AChE and BChE activity levels determined at the following frequency:
1. Before starting pesticide work/spraying (baseline).
2. First in-season test at 45-60 days.
Quarterly thereafter if spraying continues.
The Manual permits the Ellman, Delta pH, and Test-mate™ methods and refers health professionals to the CRL at the USACHPPM for details on the inter-conversion of results, which must be expressed as international units per milliliter (U/mL) on the Ellman scale for purposes of record keeping. Furthermore, the Manual does not exclude the use of alternative methods of ChE testing provided that the alternative and reference methods have at least a 0.9 correlation coefficient squared (r 2 ). The Manual stipulates that methods are unsatisfactory if they do not provide separate measures for AChE and BChE. This stipulation does not apply to chemical "surety" workers who are covered under separate policies and directives.
A final application of ChE testing in the military is associated with RDT&E. As mentioned earlier, new methods of ChE testing have been the subject of research at the WRAIR (Gordon et al., 2004) , although method development for ChE testing within the military is not a major research effort. Other applications of ChE testing involve research to study the effects of nerve agents and the efficacy of nerve agent scavengers or treatments. A summary of ChE testing applications in the military is provided in Table 1 -4. 
The Key Issue of Cholinesterase Testing versus Other Biomarkers
While ChE inhibition has been a biological marker, or biomarker, of exposure and effect for decades, it may not be advantageous for some purposes. For example, the verification of a specific agent for forensic evidence is circumstantial when using either ChE activity or enzyme levels. Many substances and physiological conditions can alter individual ChE activity, and the specific ChE-inhibitor can only be identified by analyzing the parent compound or unique metabolites. This type of identification is particularly important in incident responses involving CWAs where non-medical decisions require robust forensic evidence.
Among the methods for confirming CWA or ChE-inhibiting nerve agent exposures are the following (Worek et al., 2005 ):
1. Qualitative and quantitative analysis of nerve agent in the plasma that is unbound to ChE using chromatography and mass spectrometry (GC-MS or LC-MS/MS); 2. Qualitative and quantitative analysis of decomposition products such as phosphonic acids in the plasma and urine; 3. Fluoride-induced methods of reactivating the inhibited AChE and BChE and regeneration of the nerve agent followed by analysis by GC-MS; 4. Analysis of the proteins in plasma (BChE, albumin) using tryptic digestion and LC-MS/MS to identify adducts formed from the binding of nerve agent metabolites with peptides.
Using ChE inhibition as a biomarker also has limitations in epidemiologic studies for health risk assessments involving pesticides. Among these limitations are some of the issues discussed earlier, such as inter-and intraindividual variation and the suppression of ChE caused by health conditions or from unknown inhibitors. In addition, AChE levels in children may be different from adults, and relatively large doses of pesticides are required for significant AChE inhibition (Wessels et al., 2003) . The ideal biomarker of exposure and/or effect for epidemiologic studies is easy to analyze and sensitive and specific to the agent of interest. To this end, many potential biomarkers for pesticide exposures have been compiled, but none of them is considered ideal (Wessels et al., 2003) . Despite the shortcomings of ChE activity as a biomarker, the methods of ChE analysis are relatively inexpensive and easy to perform. The U.S. Environmental Protection Agency (USEPA) also considers AChE inhibition data useful for deriving reference doses for pesticide toxicity -provided the quality of data are considered (USEPA, 2000) . However, for the issues presented earlier in Table 1 -3, ChE inhibition may not be very helpful for health risk assessments.
As discussed earlier, the value of ChE activity as a biomarker depends foremost on the needs of the decision maker. For biological monitoring and routine medical surveillance of workers with established baselines and a known inventory of exposures to ChEinhibiting chemicals, ChE activity provides valuable information for decisions regarding the elimination of unnecessary exposures to specific chemicals. On the other hand, the use of ChE activity for forensic investigations as "smoking gun" or prima facie evidence of exposure to specific agents is very limited, albeit in combination with other supporting evidence it could be convincing. In short, the use of ChE activity for decision making should follow well-defined guidelines of interpretation that are aimed at the specific purpose of the decision.
Review of the Performance Characteristics of the Test-mate™
Cholinesterase Testing System
Introduction
Agricultural workers with exposures to organophosphate (OP) and carbamate pesticides comprise the major population that benefits from field testing of cholinesterase (ChE) activity, though residents in rural areas may also benefit from a portable and rapid screening test for ChE activity. In most cases where pesticide exposures are biologically monitored for ChE activity, the individuals are tested in a clinical setting, or a blood specimen is collected in the field and transported to a laboratory facility. Both of these approaches to biological monitoring can be time consuming and expensive. Furthermore, the time between receiving the test results and taking necessary actions to reduce pesticide exposures and/or removing the worker can be excessive. Hence, the need for a field-portable test for ChE activity has long been recognized, particularly for the lesser developed countries (Jeyaratnam, 1990 and Edson, 1950) .
Commercially-Available Field Test Kits
During the literature search for this report, only two field-portable systems were identified as commercially available for ChE testing. The oldest is the "tintometric" field kit, which has been available for over 50 years (Edson, 1950) . The current version is the Lovibond® Cholinesterase AF267 Test Kit marketed by Tintometer Limited (London, UK) . Early studies of the tintometric method concluded that the kit is adequate for determining whether "dangerous" amounts of pesticide exposure have occurred to workers (Miller and Shah, 1982) . Subsequent studies have shown that the tintometric method has insufficient agreement with the Ellman method and lacks precision to reliably establish a baseline ChE activity for workers (McConnell and Magnotti, 1994) . The main problem with the tintometric method is the use of a color comparator for semiquantitative determination of ChE activity; this non-instrumental approach is subjectively determined by the kit operator (Magnotti et al., 1988) . The most recent study of the Lovibond kit found that it performed poorly compared with available quantitative techniques (Carmona-Fonseca, 2007) .
The other widely used field-portable system for ChE testing is called the Test-mate™, manufactured by EQM Research, Inc. (Cincinnati, OH). Although a new model of Testmate™ is planned for production, the latest commercially available system is the Model 400 Test-mate™ ChE kit (Wilson, 2006) . This system requires only 10 microliters (µL) of blood, and the entire assay can be completed in less than 4 min. It weighs 10 pounds and is relatively small (11" x 7" x 10") compared with laboratory-based apparatus. The key component of this system is a fixed-wavelength absorption photometer, which is compact (3 ½" x 5 ¾" x 2") and powered by a 9-volt battery. Other components include a hard-shell case, tube rack, and reagent assay kits.
The Test-mate™ ChE system's chemistry is a variation of the Ellman method. It can specifically measure either AChE or BChE, depending on which assay kit with ChE-inhibiting reagents is used with the system (EQM Research, Inc, 2003.) . The system also measures hemoglobin and an internal reagent blank to refine photometric measurements. The results are normalized to 25°C, and with the hemoglobin concentration for AChE (Taylor et al., 2003) . The ChE activity is measured with the compact photometer, which also incorporates the electronics and algorithms to normalize the results to the other parameters. The results are usually expressed in U/mL, or alternatively for AChE as activity per gram of hemoglobin (U/g Hgb).
The Test-mate™ is the only known field-testing system for ChE that is "approved" by the U.S. Food and Drug Administration (FDA). This "approval" is actually a concurrence by the FDA that Test-mate™ is "substantially equivalent" to other cholinesterase test systems, which means it is a Class I medical device with a Premarket Notification and a 510(k) submission (21 CFR 862.3240). Unlike a Premarket Approval, the 510(k) is a Premarket submission to the FDA that must demonstrate the device is substantially equivalent to a legally marketed device. In other words, the manufacturer must have data to support the claim the device is substantially equivalent to a predicate device or method. After the claim is reviewed and the assertion of substantial equivalence is concurred by the FDA, a letter of determination is sent to the manufacturer that allows interstate marketing of the device without the need for Premarket Approval, a much more complex approval process.
Literature Review of the Test-mate™ Field Kit
Early published studies that laid the groundwork for the Test-mate™ kit were by Magnotti et al. (1987 Magnotti et al. ( , 1988 . The authors optimized the Ellman-based AChE and BChE chemistry for field use and employed a battery-operated Model 176 colorimeter by EQM Research, Inc. (Cincinnati, OH), the manufacturer of the current Test-mate™ kits. For comparison purposes, they also used the semi-quantitative Lovibond tintometric field kit. The two methods had only a fair agreement (r 2 = 0.841), and in some patient cases the tintometric method indicated normal ChE activity when it actually was depressed to the point of severe intoxication (Magnotti et al., 1988) . The authors also defined the optimal criteria for a field kit to measure ChE:
1. Ability to accurately and specifically measure erythrocyte and/or plasma cholinesterase.
2. Low cost.
3. Precision to determine a baseline pre-exposure value for erythrocyte and/or plasma cholinesterase for subsequent comparison during exposure.
4. Stability of reagents to varying temperature and humidity for at least several months.
5. Being operational without need for line voltage, a balance, or a centrifuge.
Portability.
7. Capacity to analyze, reasonably quickly, a large number of samples in the field. (Magnotti et al., 1988) The earliest published study that specifically mentions a Test-mate™ kit was by McConnell et al. (1992) . Recognizing the importance of the interindividual variability of ChE, the authors used an early model of Test-mate™ to characterize the AChE variability of workers at a pesticide formulation plant in Mexico. They discovered the AChE coefficient of variation (CV) was similar to that in previous studies, approximately 12%. However, when the researchers adjusted the AChE to the hemoglobin, the CV was reduced markedly to 7.4%. This underscores the importance of measuring the hemoglobin when using Test-mate™ to measure AChE activity. Although the authors stated that the Test-mate™ normalized the AChE activity to 25°C, they did not state the temperature conditions at which the assays were performed. Karr et al. (1999) evaluated the Test-mate™ kit with respect to its feasibility and capability to detect ChE depression among orchard workers. Although this study was published in 1999, the actual project was conducted during the apple-growing season of Washington State in 1993. The specific version of the Test-mate™ used was the Testmate™ OP kit, and several issues were experienced while using it during the study. The most significant issue was a recall of the Test-mate™ kits by the manufacturer for a faulty filter component that could alter the kit's accuracy over time. Anticipating potential problems, the authors measured ChEs from 26 unexposed employees prior to returning the kit and after receiving the modified kit. They discovered the mean baseline values for AChE and BChE activity decreased by 10.3% and 15.9%, respectively. Therefore, before the trend in ChE activity of the orchard workers could be analyzed, the authors had to lower the pre-recall ChE activity data by the mean difference values of the unexposed group.
Another technical issue experienced by Karr et al. (1999) with the Test-mate™ was related to the functional temperature range of the kit. Prior to initiation of the study, the authors conducted laboratory-based experimentation with the Test-mate™ and identified inaccuracies at low temperatures (<18°C). An attempt was made to conduct all ChE monitoring of orchard workers in situations where the temperature was at or above 18°C. During one month of the study, however, this was not possible, and the data obtained during that period was excluded from analysis.
Despite the issues encountered with the Test-mate™, the study by Karr et al. (1999) provided useful information for conducting field monitoring of ChE. One advantage of the Test-mate™ kit was the use of fingerprick collection of blood instead of venous puncture. The fingerprick collection was more agreeable to the orchard workers and reduced potential exposures to blood borne pathogens from needle sticks. However, a problem was identified with pesticide residues on the skin that can contaminate fingerprick specimens, resulting in erroneous ChE activity measurements. Another important observation was the effect of BChE depression of workers with hepatotoxicity from isoniazid therapy. The authors also identified and confirmed significant levels of ChE depression among particular orchard workers. Furthermore, they observed a difference in the trends between AChE and BChE activities over the growing season, i.e., AChE was more indicative of cumulative exposures, while BChE was more responsive (suppression and recovery) to short-term exposures.
Using an early model of the Test-mate™ kit, London et al. (1995) encountered some problems with its sensitivity. The researchers measured the activity of both AChE and BChE under three conditions: (1) field application of the Test-mate™, (2) non-field application of the Test-mate™, and (3) in the laboratory using the Ellman method. The blood specimens were collected from agricultural workers during ambient temperature ranges from 20°C to 28°C. Compared with the laboratory-based Ellman method, the Test-mate™ demonstrated much less sensitivity to drops in both AChE and BChE activity. Nevertheless, the authors concluded that the AChE activity measurements were sufficiently repeatable for routine surveillance. On the other hand, the BChE activity measurements were deemed not sufficiently repeatable for routine surveillance. The authors also offered several possible explanations for the poor repeatability of the Testmate™ kit. One suggested explanation was that the Test-mate™ has inherent problems with differences in the ambient temperatures, while other explanations involved the relative skill of the operators and the more precise and controlled preparatory steps used with the apparatus of permanent laboratories (London et al., 1995) .
In response to the findings of poor performance with the Test-mate™ kit by London et al. (1995) , a comment was later published by Amaya et al. (1996) . The authors reiterated that the Test-mate™ performed with good reproducibility under similar circumstances in a previously reported study (McConnell et al., 1992) . To better understand the conflicting views of performance with the Test-mate™ kit, Amaya et al. (1996) conducted additional experiments. Using blood samples split into six separate aliquots, the Test-mate™ was used to measure AChE and BChE activity at different ambient temperatures. Their data demonstrated that the temperature normalization adjustment by the Test-mate™ was the source of significant error for both AChE and BChE activity. In another experiment, they examined the rate of thermal equilibration of the Test-mate™ after moving it from a cool room (8°C) to warmer room (40°C). The Test-mate™'s internal thermometer registered only 30°C after 120 min in the room with an ambient temperature of 40°C. They suggested that rapid changes in temperature with the Test-mate™ immediately before measuring ChE activity would result in considerable error. The authors further suggested this problem might be solved if the Test-mate™ manufacturer were to modify the kit to measure the temperature of the reagent solution rather than the colorimeter.
Three additional studies were published using the Test-mate™ to measure ChE activity levels among workers and residents exposed to organophosphate (OP) pesticides. Ciesielski et al. (1994) used an early version of the Test-mate™ kit to identify significant differences in AChE activity between farm workers and non-farm workers. Among the farm workers, they determined that AChE activity was lower specifically with the pesticide applicators, and they found a strong association of illness symptoms (diarrhea) with lowered AChE activity levels. The Test-mate™ (Model 176 colorimeter) was also used in a study that determined rural residents who are potentially exposed to pesticides had lowered AChE activity levels and a greater proportion of illness symptoms compared with a similar population without pesticide exposures . TinocoOjanguren and Halperin (1998) also used the Test-mate™ OP kit to compare the AChE activity rates of residents among different communities in Mexico; their results suggested that the poorest communities were at greater risk of health effects from pesticide exposures. While the Test-mate™ proved to be a useful tool for studying pesticide exposures and toxicity under field conditions, the analytical precision and accuracy of the Test-mate™ kits were not included in the design of these studies. Consequently, the validity of the data collected during these studies is questionable.
One of the most comprehensive field studies attempted with respect to exposure parameters was conducted by Simcox et al. (1999) . This study followed orchard workers over an apple-thinning season and sampled a variety of exposure parameters to an OP pesticide, including environmental concentrations and biological monitoring. The latter parameters included urinary metabolites of the pesticides, and AChE and BChE activity using the Test-mate™ kit. The urinary metabolites were analyzed at a fixed laboratory, while the Test-mate™ determinations of ChE activity were performed on-site near the workers and control subjects. However, the results of the Test-mate™ were anomalous in some cases, and the authors were concerned about previous reports of erroneous temperature corrections by the Test-mate™. Since the temperature changes varied greatly during the seasonal study, the authors considered the performance of the Test-mate™ unreliable and excluded its results from their study.
After having gained experience with the strengths and limitations of the Test-mate™ kit, McConnell et al. (1999) studied the BChE activity of children potentially exposed to OP pesticides. Instead of using automated algorithms in the Test-mate™, the authors used a correction chart provided by the manufacturer to manually adjust BChE activity for ambient temperatures. After finding a significant difference in the BChE activity levels between exposed and unexposed children, the authors wished to verify the difference was not due to Test-mate™ temperature-correction errors. The authors used the corrected mean BChE activity data and dummy variables with multiple linear regression modeling; the results indicated a difference in BChE activity (albeit slightly less) still remained between the exposed and unexposed children. This quality control approach involved only statistical manipulation and not the use of analytical standards or verification by laboratory analysis.
As part of a multifaceted study, Higgins et al. (2001) measured the AChE activity migrant workers and their children using the early model Test-Mate™ OP kit. During the study in 1998, the Test-mate™ OP kit was replaced by EQM Research, Inc. with the Model 400 Test-mate™ ChE kit, and supplies for the old model were no longer available. The authors then initiated a validation study to compare the performance of the Model 400 Test-mate™ ChE kit with the laboratory-based Ellman method. They also compared the performance of the old and new models of the Test-mate™ kits. Blood samples for the validation studies were taken from staff volunteers and diluted serially to yield varying degrees of AChE activity. All analyses using the Test-mate™ kits and the Ellman method were conducted at temperatures of approximately 25°C. As an added measure of validation, the authors also evaluated the hemoglobin measurements of the Test-mate™ kits against the HemoCue system (HemoCue AB, Angelhom, Sweden). The following results and conclusions are summarized from their study:
1. Although the measurements of AChE activity of undiluted blood using the Test-mate™ were approximately 87% of the AChE activity compared with the benchmark Ellman method, a strong linear relationship existed between the Test-mate™ and Ellman methods using serially diluted blood to yield varying degrees of AChE activity. The correlation coefficient squared (r 2 ) between the methods was 0.98.
2. The measurements of hemoglobin by both the old and new Test-mate™ kits were significantly lower compared with the benchmark HemoCue kit. In addition, the hemoglobin measurements between the old and new Test-mate™ kits were significantly different, with the old kit providing consistently lower results.
3. The paired AChE activity levels of the old Test-mate™ OP kit were significantly and consistently lower compared with newer Model 400 Test-mate™ ChE kit. However, when the results of both kits were corrected for hemoglobin, the results were no longer significantly different, despite the fact that each kit yielded different results for hemoglobin.
The authors noted several improvements in the Model 400
Test-mate™ ChE kit over the old model. Among them was a better method for sample preparation and sample absorbance at 450 nm (vs. 470 nm) against a reagent blank.
5. The authors observed differences in reliability of the Test-mate™ kits based on the experience of the operator. Novice operators had more problems than seasoned operators did. The modifications to the new Model 400 Test-mate™ ChE kit improved the ease of use and eliminated some operator errors in sample preparation.
6. The authors reiterated that technique of choice for surveillance is the use of urinary metabolite levels and benchmark ChE activity levels (using the laboratory Ellman method) with established baseline data. Nonetheless, they concluded that when used properly, the Test-Mate™ kit provides useful data on OP exposures.
To evaluate the performance of the Test-mate™, Oliveira et al. (2002) tested three models or versions of the Test-mate™ kit. One of the kits was the latest Test-mate™ Model 400 ChE, while the other two kits were earlier versions. Using fetal bovine serum as a source of AChE, the authors tested the performance over a temperature range from 10° to 37°C. The results of the Test-mate™ kits were compared with the laboratorybased Ellman method using a 96-well microplate reader. As expected, the uncorrected AChE activity of the fetal calf serum sample increased with increasing temperatures using the laboratory-based microplate reader. On the other hand, the Test-mate™ kits automatically normalized the AChE activity to 25°C by an internal program; none of the Test-mate™ kits displayed the uncorrected AChE activity, i.e., the operator relied entirely on the hardware and internal algorithms for temperature-corrected results.
The two old versions of the Test-mate™ kits did not satisfactorily normalize AChE activities at temperatures below 25°C. Most importantly, the values between the three Test-mate™ kits were not comparable to one another without some external standardization. The performance of the newer Test-mate™ ChE Model 400 kit was generally satisfactory only from 20-37°C. However, although the performance was satisfactory at these temperatures, the Test-mate™ ChE Model 400 kit yielded higher percent error rates at all temperatures compared with the laboratory-based microplate reader. The authors recommended that the Test-mate™ be used with a laboratory standard and under carefully controlled temperature conditions. Furthermore, the authors expressed concern about the validity of ChE data collected in the field using the Testmate™ without the aforementioned controls. Despite these shortcomings, the authors stressed the need for a portable and inexpensive device to rapidly measure ChE activity in the blood (Oliveira et al., 2002) .
Shortly after the Oliveiri et al. (2002) study, the Test-mate™ kit was used in a study of human blood samples spiked with variable amounts of the nerve agent soman (GD). Unlike the previous study, which used several versions of the Test-mate™, this study used three of the latest Model 400 Test-mate™ ChE kits, and the assays were run under normal temperature-controlled conditions in both a mobile laboratory (520 th Theatre Army Medical Laboratory) and a permanent-structure laboratory (Taylor et al., 2003) . Along with the control samples, the study included blood samples spiked with GD at levels designated as high, medium, and low. The blood samples were blinded to the Testmate™ operators and used to examine the precision of the three kits in terms of repeatability (measurements in a single run or day) and reproducibility (measurements across runs or days). The following summary of observations and conclusions regarding the performance of the Test-Mate kits came from the study:
1. Using analysis of variance, significant differences in repeatability of AChE activity were observed between the three Test-mate™ kits.
2. Comparison of each kit's CV by GD dose revealed no significant differences in repeatability between the three Test-mate™ kits.
3. No significant differences were observed in daily mean levels of AChE activity among the Test-mate™ kits, implying each kit had reproducible results across the days.
4. The Test-mate™ kit had greater precision with the smaller doses of GD, i.e., less inhibition and thus greater AChE activity.
5. The AChE activity normalized to hemoglobin was more precise compared with using only blood volume.
6. The more experienced kit operator had the most precise results.
7. The lower limit for ambient temperatures when using the Test-mate™ kit should be 20°C.
8. Even though some variability in repeatability exists within GD doses among the Test-mate™ kits, the control samples were easily distinguished from all GD-spiked samples.
9. The CVs of all control samples were 3% or less, which lead the authors to conclude that the precision of the Test-mate™ kit is excellent and its performance is acceptable.
Under a contract by the U.S. Army Medical Research and Materiel Command (USAMRMC), the performance of the Test-mate™ Model 400 kit was compared with the laboratory Delta pH and Ellman methods (Wilson, 2006) . Along with evaluating the performance of these methods, the goal was to derive conversion equations for AChE activity between the different methods for the direct comparisons. After obtaining blood samples from human volunteers, the red blood cells were separated and spiked with different concentrations of ChE-inhibitors to yield a range of AChE activity, which was then measured by the different methods. Initially, Wilson was to receive a customized Test-mate™ kit from the manufacturer that would provide direct read-out of AChE activity without correction or normalization for temperature. However, the manufacturer (EQM Research, Inc.) did not provide the customized Test-mate™, and the study was conducted with the standard Model 400 Test-mate™ ChE kit. Although not specifically stated in the contract report, it is assumed that the Test-mate™ was operated in the laboratory under normal and controlled temperature conditions.
As measured by linear regression, the overall agreement of the Test-mate™ and the Delta pH methods was excellent, resulting in r 2 = 0.99. The agreement of the Test-mate™ and Ellman Methods resulted in r 2 = 0.91. Similarly, the agreement between the Delta pH and Ellman methods resulted in r 2 = 0.92. One explanation for the slightly lower r 2 with the Ellman method appears to be the greater sensitivity of the Ellman method at higher levels of AChE activity compared with both the Test-mate™ and Delta pH methods. The inferred conclusion is that the AChE activity must be more depressed for detection by the Test-mate™ or Delta pH methods, whereas the Ellman method is more sensitive at detecting lower levels of exposure to ChE inhibitors (Wilson, 2006) .
Conclusions
Despite its longevity, the tintometric field kit is limited to semi-quantitative estimation of ChE activity. This kit is not reliable for establishing baselines of ChE activity and may not detect significant depression of ChE activity. Hence, its utility is very limited in terms of biological monitoring and medical surveillance.
The Test-mate™ system has 20 years of published history on its use, including several validation studies. Despite the Test-mate™'s shortcomings, it represents the best commercially available field test kit for ChE activity. The manufacturer has also endeavored to improve the Test-mate™ system when problems were identified through user feedback and publications. Based on the publications reviewed in this report, the following conclusions are offered:
1. The Model 400 Test-mate™ ChE kit appears to provide valid results for AChE activity under steady temperature conditions above 20°C and when used by an experienced operator.
2. The normalization of AChE with hemoglobin is preferable in terms of reduced interindividual variability and the comparison of results.
The interpretation of BChE activity measured with the Model 400 Test-mate™
ChE kit is less definitive, but the instrument probably provides sufficient accuracy and precision to detect significant depression levels of BChE activity, i.e., 20-40% depression from baseline .
4. The compactness of the Test-mate™ system, along with method of blood collection (fingerprick) and the time to obtain results are definite advantages over laboratory-based determinations of ChE activity. 5. Precautions are necessary when collecting blood specimens to prevent unintentional contamination with pesticide residues.
6. Desirable modifications to the Model 400 Test-mate™ ChE kit would include an additional display/recording of AChE activity uncorrected for temperature, and the use of analytical standards for calibration or quality assurance purposes.
7. Earlier models of the Test-mate™ are not reliable for routine biological monitoring of either AChE or BChE activity.
Survey of Handheld and Portable Devices for Measuring Biological Markers
Introduction
This survey is not an exhaustive inventory of all handheld or portable devices that measure biological markers. An all-inclusive list of such devices -particularly those in the research and development (R&D) stages -would be expensive, time-consuming, and difficult to compile. The identification of private industry projects is difficult due to the intellectual property issues and because publications and advertisements about them are rare during the R&D stages. Federally funded R&D projects (including military Research, Development, Testing and Evaluation; or RDT&E projects) are often fragmented and span many departments and agencies across the government. While this fragmentation can foster competition and innovation, it also results in a lack of communication, cooperation, and coordination -making discovery very difficult. Therefore, the discussion within this report is limited to handheld or portable devices that are readily discoverable and/or commercially available for measuring biological markers.
Currently Funded Projects
An inquiry was made to the Research Area Directorates of the U.S. Army Medical Research and Materiel Command (USAMRMC) for a list of all intramural projects to develop handheld or field-portable devices that can measure biological markers of interest, e.g., antibodies to infectious agents, chemical or biological warfare agents, toxic industrial chemicals, etc. Only five projects were identified, and these are listed in Table  3 -1 along with two other devices that are discussed later.
The first three projects in Table 3 -1 were sponsored by the Defense Threat Reduction Agency (DTRA). This agency centrally funds many research projects related to defense against weapons of mass destruction, including biological and chemical warfare agents (BWAs and CWAs). While some information about the DTRA's projects is available, many of the projects and their details are classified, and information about them is difficult to obtain. Multiple projects related to detecting BWAs and CWAs are likely being funded by the DTRA and may be in various stages of R&D. However, before any device that involves medical surveillance or clinical decision making can be fielded, it requires a 510(k) review by the U.S. Food and Drug Administration (FDA), and the USAMRMC is usually the lead agency for fielding such military medical devices. 
USAMMDA
Of the three DTRA-sponsored projects listed in Table 3 -1, the most relevant one to this survey is the blood cholinesterase (ChE) assay by Dr. Richard Gordon of the Walter Reed Army Institute of Research (WRAIR). Dr. Gordon has developed a novel method of measuring acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (Gordon et al., 2004) . The primary objective of this DTRA-sponsored work is to develop a sensitive and high throughput laboratory method for measuring ChEs. Current funding of the laboratory ChE device at the WRAIR is aimed at developing Good Laboratory Practice standards. Dr. Gordon also initiated and managed a project with Kumetrix, Inc. (Union City, CA) to develop a handheld device for measuring ChEs. Unfortunately, the DTRA funding for the handheld device was discontinued, and the project is currently inactive, awaiting additional funding (telephone conversation with Richard Gordon on November 8, 2007). In a telephone conversation with Brian Sullivan of Kumetrix, Inc. on February 1, 2008, it was learned the company is also being funded by DTRA to detect a protein biomarker for BWA exposures/effects; this project is receiving oversight from the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD). In addition, Kumetrix, Inc. is working with USAMRICD on a handheld device to detect specific CWAs as part of a Small Business Innovation Research (SBIR) award, now in Phase II funding.
The fifth project in Table 3 -1, also funded by an SBIR award, involves the U.S. Army Center for Environmental Health Research (USACEHR) and Siloam Biosciences, LLC (Cincinnati, OH). The objective of this project is to develop one handheld device with interchangeable "biochips" capable of measuring several biological markers or chemical residues: AChE and BChE, metallothionein, and blood lead. The biochips are fabricated on the basis of Bio-MicroElectroMechanical System concepts and employ an immunoassay detection technology. The project was initiated in 2005, and funding is expected to be terminated in February 2008, at which time a functional handheld device with prototype biochips are expected to be demonstrated.
A request was made in December 2007 to the Telemedicine and Advanced Technology Research Center (TATRC) of the USAMRMC for a list of handheld or portable devices under development. The TATRC database of funded projects was searched using the terms "portable," "handheld," and "point of care." Twenty-four projects were identified in the search, but twenty-three of them were solely involved with information management/information technology -not the actual measurement of biological markers (Eva Lai, December 26, 2007, email message to author). Only one portable device actually measured a biological marker: The GlucoScope Monitor by Visual Pathways, Inc. (Prescott, AZ), designed for use by diabetics to non-invasively measure their blood glucose (Table 3-1) .
Within the DoD, the USAMRMC is responsible for advanced development and fielding of military medical equipment, including handheld or field-portable medical devices, for all the branches of service. This responsibility is accomplished through a subordinate command called the U.S. Army Medical Materiel Development Activity (USAMMDA).
To date, only one portable or point of care device has been developed and made ready for fielding: The Binax Now® Malaria Test. This device ( November 27, 2007 , email message to author). These interests are broad and limited mostly by budget constraints and the maturity of technologies. Except for commerciallyavailable technologies such as the Test-mate™ ChE test kit, most current efforts appear to involve research with laboratory-based technologies. One novel, portable and mature technology was identified to measure anti-anthrax protective antigen immunoglobulin G in serum and whole blood (Biagini et al., 2006) .
With the exception of DoD and a few other federal agencies, most funding by the federal government for biomedical technology development is limited to the basic and applied research phases of the R&D process. The final engineering development, production, and marketing of medical devices are usually accomplished through the private sector. However, two federal programs called the SBIR Program and the Small Business Technology Transfer (STTR) Program are intended to spur the advanced development and commercialization of technologies. For most federal agencies, the SBIR/STTR programs provide the sole opportunity to sponsor advanced development of a technology or device.
A database of SBIR/STTR project awards is maintained by the Small Business Administration (http://www.sba.gov/SBIR/indexsbir-sttr.html). Several searches (nonBoolean) of this database were conducted using the following terms: biological monitoring, biomonitoring, biomarkers, and point of care. Only a few projects were identified using the terms biological monitoring and biomonitoring, and among them only two were relevant to this survey. In contrast, a great number of projects were identified using the terms biomarkers (190 total projects) and point of care (133 total projects). This greater number of projects reflects a growing trend in biomarkers discovery research and point of care devices, which are discussed more fully in the next section of the report. The success rates of SBIR/STTR projects are not readily available from federal agencies or tracked in accessible databases. This may stem from a number of reasons, including the licensing or selling of technologies by small businesses to larger corporations that can produce and market the new technologies. Many of the technologies discussed in the next section of the report may have been initially funded from federal research budgets such as the SBIR/STTR programs.
Leveraging Opportunities with Commercially-Ready and -Available POC Devices
While the number of portable or hand-held devices for biological monitoring of toxic chemicals is limited, a growing number of portable devices are being marketed for clinical healthcare. These devices are referred to as either POC, near the patient, bedside, or extra laboratory testing (Price, 2001) . In recent years, the trend in the development and commercialization of these devices has created a new segment in the medical market called POC Diagnostics. More precisely, the following definition has been proffered: "POC Diagnostics are composed of tests that are performed near the patient and over the counter/patient self testing that require a quick turnaround time and do not require permanent dedicated space in a clinical laboratory" (Scientia Advisors, 2007) .
The advent of POC diagnostics is made possible from technological advances in materials science, chemistry, molecular biology, and electronics. These enabling technologies have achieved greater sensitivity and permitted the miniaturization of laboratory testing, along with the identification of new biological markers for clinical applications. The majority of growth in the market for POC diagnostics has been in the testing of diabetics, but the market for other testing and diseases is expected to increase from $2.8 billion in 2005 to $4.2 billion in 2010 (Scientia Advisors, 2007) . Figure 3 -1 illustrates the projected growth in the market by the specific application or disease; this figure excludes diabetes and pregnancy testing, which constitute the majority of the POC diagnostics market segment. On the other hand, the POC market for public health services (e.g., biological monitoring) is not even acknowledged in most economic reports or market projections. A review of U.S. disaster planning documents and the public health literature revealed little or no mention of POC devices (Kost, 2006) . The primary reason that POC devices have been overlooked is uncertain, but it may be related to the high cost of product development/approval relative to the small market size of public health services. In addition, expensive or advanced technologies are often unaffordable by many state and local health departments. The expansion of the healthcare market for POC diagnostics will eventually result in economies of scale and competition, possibly making such devices more available and affordable for public health services. This process may also be accelerated by generous donations from private entities such as the Bill and Melinda Gates Foundation. Under its initiative titled "Grand Challenges in Global Health," the Foundation has awarded millions of dollars to develop POC devices for diagnosing diseases in the developing world (Yager et al., 2006) .
After an extensive review, compendia of POC tests and devices were compiled by Tran and Kost (2006) for mobile, emergency, critical and primary care; and infectious diseases. Approximately 150 different instruments or platforms were identified for POC diagnostics and testing. The medical care instruments were categorized as handheld, portable, transportable, or for personal monitoring (ex vivo or in vivo placement). Only one commercial device was identified in the personal monitoring category, and that device is now defunct. The infectious disease tests were categorized as chip, disposable reagent, disposable reagent kit, and nucleic acid testing. The authors concluded that POC testing is becoming "smaller, smarter, faster and cheaper" in all areas of application (Tran and Kost, 2006) . Tables 3-2 and 3-3 provide an overview of the compendia for clinical care and infectious diseases, respectively. Many of the system components for POC devices conceivably could be modified or reengineered for other applications in public health, including biological monitoring for deployment health surveillance. For example, the POC applications for drug-of-abuse screening, emergency diagnosis of a drug overdoses, and the monitoring of medication dosage (Melanson, 2006 and are technically similar with the biological monitoring of exposure to industrial and agricultural chemicals. The characteristics of POC devices for drug-of-abuse testing have been reviewed by , and these characteristics are very similar to hand-held or portable devices that may be used for biological monitoring. An important point, however, is that no single underlying technology can accommodate all types of desired testing. Some devices could be multiplexed or have interchangeable chips that can perform multiple types of testing, but several POC devices would likely be needed to perform biological monitoring because of the diversity of analytes and measurement technologies.
Conclusions and Recommendations
Leveraging the Growing Market in POC Diagnostics
As discussed in chapter three of this report, the POC diagnostic kits and devices represent a growing business market. The demand for POC devices is expected to dramatically increase, and private investors, along with nonprofit foundations, will likely continue investing in advanced development of these technologies. The types of tests performed or biomarkers measured will be driven by the demands of patients and the healthcare industry. Unfortunately, without government support, the development of POC devices specifically for public health applications (including ChE testing) will lag far behind development for the healthcare industry.
For biological monitoring applications such as ChE testing, an opportunity exists to leverage the development trend of POC devices by the healthcare industry. A good leveraging strategy would begin by identifying POC devices that have already reached technological maturity to receive FDA clearance/approval for patient testing. A systems analysis of selected devices could then be undertaken to determine if a component or subsystem could be modified to measure specific biomarkers (e.g., ChEs) for public health applications or military deployment health surveillance. Assuming that intellectual property issues can be resolved, this strategy would minimize government investment and reduce the risk of failure.
An important shortcoming of most POC devices is that they are not suitable for the rigors of field conditions, e.g., the tailgate of a truck. Most POC devices for the healthcare industry are designed for permanent building structures and countertops such as found in a physician's office or examination room. Such environments are usually protected from the weather and have normal/stable relative humidity and temperature. Therefore, in addition to re-engineering components of a POC system, additional investment and engineering may be necessary to "harden" a POC device for field use.
Suggested Ideal Performance Characteristics of a Field Cholinesterase Testing Device
For civilian public health applications, the performance characteristics of a field ChE test device for biological monitoring of pesticide workers have been articulated by Magnotti et al. (1988) and discussed in chapter two of this report. For military health surveillance applications, some general guidance about ChE testing exists within various military documents (discussed in chapter one), but the desired performance characteristics of a military field ChE test device have not been formalized into criteria. The process of developing performance criteria usually involves the combat developer/doctrine centers and the materiel developer. The first step should involve developing a concept of operations (CONOPS) for ChE field testing devices.
Since a CONOPS specifically for field ChE test devices has not been developed, the performance characteristics described below were derived from documents reviewed for this report. These performance characteristics should not be considered formal or final. Nevertheless, they represent a reasonable starting point for discussion and eventual incorporation into performance criteria.
1. Monitored Parameters, Sensitivity, and Accuracy.
a. The field ChE test device should accurately and specifically measure blood acetyl cholinesterase (AChE) and butrylcholinesterase (BChE) activities.
b. The benchmark performance standard for most organizations is the Ellman method performed by a credible laboratory. Comparisons between different methods requires conversion formulae, and the agreement between methods must have at least a 0.9 correlation coefficient squared (r 2 ) (DoD, 2007).
c. To attain FDA's 510(k) clearance as "substantially equivalent" to existing ChE test methods, the appropriate performance analysis must be performed. Guidance on performance analysis in terms of reliability, validity, and add-on value is provided elsewhere (Schwenke, 2007) . The suggested analysis is the Bland-Altman statistical approach for the comparison of methods (Nizamettin Gul, January 10, 2008, email message to William van der Schalie). d. Hemoglobin should be accurately measured and used to normalize AChE activity. e. A reference or ghost standard should be used with the device to ensure performance reliability.
Precision.
a. Precision must be sufficient to determine baseline pre-exposure values for AChE and BChE activities and for subsequent comparisons during exposure, thus permitting the detection of "significant" exposures.
b. The definition of "significant" exposure may vary, but generally a reduction of 80 percent below baseline activity of either AChE or BChE is necessary for retesting and/or investigation of exposures (Cal/EPA, 2002) .
c. Acceptable precision in terms of repeatability (measurements in a single run or day) and reproducibility (measurements across runs or days) as previously described are also necessary (Taylor et al., 2003) .
3. Cost.
a. To be cost-effective, the device and reagents should be affordable to both the military and civilian public health agencies.
b. The benchmark of cost is the Model 400 Test-mate™ ChE kit, which currently costs less than $3,000. Reagent kits for 96 tests generally cost a few hundred dollars.
4. Stability of Reagents and Consumable Supplies. a. As specified by Magnotti et al. (1988) , the reagents and consumable supplies should be stable to varying temperature and humidity for at least several months.
b. More specific requirements for the stability of reagents and supplies may be needed for military logistical support, depending upon the CONOPS.
Environmental Conditions.
a. For military medical applications, the device's performance under various environmental conditions is greatly dependent upon the CONOPS. At a minimum, the device should exceed the operational limitations of the Model 400 Test-mate™ ChE kit determined by the literature review:
i. Operational Temperatures. The device must perform reliably in less than an hour after common temperature fluctuations (e.g., removal from a vehicle to an outdoor test site) and at ambient temperatures lower than 20°C, and ideally at a range from 8°C to 40°C.
ii. Humidity Conditions. With respect to relative humidity, the device's operational performance should be consistent in a wide range of climates, from deserts to jungle environments.
iii. Ruggedness or Shock/Vibration Tolerance. The device should be shock resistant and made with hardened materials to withstand transport and use under normal field conditions. Specific criteria for field military medical devices may be available and should be used.
6. Portability: Size, Weight, Cube, and Logistics.
a. The desired portability is a handheld device about the size of a Personal Digital Assistant. However, this level of portability may be difficult to achieve without compromising other performance characteristics.
b. To have added value, the portability of any new device should be better than the Model 400 Test-mate™ ChE kit: i. Weight: 10 pounds.
ii. Kit size in case (cube): 11" x 7" x 10".
iii. Size of fixed-wavelength absorption photometer: 3 ½" x 5 ¾" x 2".
iv. Transportable in a hard-shell case.
7. Power Requirements.
a. The field device should be operational without need for line voltage, a balance, or a centrifuge.
b. The minimum performance benchmark is the Model 400 Test-mate™ ChE kit, which operates using a 9-volt battery.
8. Speed, Sample Size, and Throughput. a. The device should have the capacity to analyze a large number of samples in the field in reasonably quick time (Magnotti et al., 1988) .
b. The minimum performance benchmark is the Model 400 Test-mate™ ChE kit:
i. The sampling method should consist of a finger prick and sample size approximately of 10 microliters (µL) of blood.
ii. The entire test for one sample should be performed in less than 4 minutes.
9. Operator Training and Device Complexity/Reliability. a. Ideally, a device for field ChE testing should be automated, requiring little operator training and allowing minimal opportunity for human error/variability in the results. This ideal is difficult to achieve and is complicated by the Clinical Laboratory Improvement Amendments (CLIA) passed by Congress in 1988.
b. CLIA regulates all laboratory testing, including POC testing and the Testmate™ ChE kit. Consequently, all POC testing sites are subject to CLIA regulations, which may include compliance with a number of quality control practices, depending upon the complexity of the tests performed. Ideally, a field device should be CLIAwaived, but in any case it should not exceed "moderate" complexity. Specific military medical guidelines should be followed regarding compliance with CLIA.
c. The device should also be capable of providing the data behind "black box" results -i.e., the device should provide raw instrument signal data as well as providing test results that have been normalized or corrected for temperature and other variables such as hemoglobin.
d. As mentioned above, a reference or ghost standard should be available and used with the device.
Conclusions on the Status of Handheld or Portable Devices for Measuring Blood Cholinesterase
Based on the literature review and interviews conducted for this report, only one "device" has been validated for cholinesterase (ChE) testing in the field: the Model 400 Testmate™ ChE kit by EQM Research, Inc. (Cincinnati, OH). This test kit has been developed and improved over the course of twenty years and is the only field kit or device that has been reviewed by the U.S. Food and Drug Administration (FDA) and judged "substantially equivalent" to commercially-available ChE test systems used by clinical laboratories. Despite its development and application history, the Model 400 Test-mate™ ChE kit is not an ideal system for field use, and several issues discussed in chapter two of this report remain unresolved.
In recent years, a few companies with the support of federal funding have attempted to develop handheld or portable devices for ChE testing. However, the challenges of engineering a microfluidic "chip" that incorporates ChE test chemistry is daunting and must pass several hurdles before "substantial equivalence" is granted by the FDA. New handheld or portable devices must be subjected to rigorous paired testing and compared with the Ellman test method performed by a credible laboratory. Furthermore, before new devices can be used in the field, they must perform satisfactorily and consistently under a diverse set of environmental conditions. To date, no handheld or portable device has reached sufficient maturity to meet all the desired performance characteristics -including the Model 400 Test-mate™ ChE kit. 
